The anti-tumor effect of A3 adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Vincenzi, Fabrizio ^a   Targa, Martina ^a   Corciulo, Carmen ^a   Gessi, Stefania ^a   Merighi, Stefania ^a   Setti, Stefania ^b   Cadossi, Ruggero ^b   Borea, Pier Andrea ^a   Varani, Katia ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b Igea Biophysics Laboratory   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENYLATE CYCLASE; CASPASE 3; CYCLIC AMP; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; PROTEIN P53; THYMIDINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CELL; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; ELECTROMAGNETIC FIELD; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; GLIOBLASTOMA; HUMAN; HUMAN CELL; NERVE CELL CULTURE; NONHUMAN; PHEOCHROMOCYTOMA CELL; PROTEIN SYNTHESIS; PULSED ELECTROMAGNETIC FIELD; RAT; RECEPTOR UPREGULATION; STIMULUS RESPONSE; UPREGULATION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; ELECTROMAGNETIC FIELDS; HUMANS; NEURONS; NF-KAPPA B; PC12 CELLS; RATS; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A3; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84862695783     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039317     Document Type: Article

References (60)

1. Borea PA, Gessi S, Bar-Yehuda S, Fishman P, (2009) A3 adenosine receptor: pharmacology and role in disease. Handb Exp Pharmacol 193: 297-327.
2. Gessi S, Merighi S, Varani K, Borea PA, (2011) Adenosine receptors in health and disease. Adv Pharmacol 61: 41-75.
3. Varani K, Padovan M, Govoni M, Vincenzi F, Trotta F, et al. (2010) The role of adenosine receptors in rheumatoid arthritis. Autoimmun Rev 10: 61-64.
4. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA, (2011) Adenosine receptors and cancer. Biochim Biophys Acta 1808: 1400-1412.
5. Fishman P, Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, et al. (2009) Adenosine receptor and cancer. Handb Exp Pharmacol 193: 399-441.
6. Fishman P, Bar-Yehuda S, Madi L, Cohn I, (2002) A3 adenosine receptor as a target for cancer therapy. Anticancer Drugs 13: 437-443.
7. Fishman P, Bar-Yehuda S, Ohana G, Barer F, Ochaion A, et al. (2004) An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene 23: 2465-2471.
8. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, et al. (2003) A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100: 31-48.
9. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, et al. (2008) The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 117: 123-140.
10. Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, et al. (2008) The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol 33: 287-295.
11. Fishman P, Bar-Yehuda S, Ohana G, Barer F, Ochaion A, et al. (2004) An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. Oncogene 23: 2465-2471.
12. Fishman P, Bar-Yehuda S, Ardon E, Rath-Wolfson L, Barrer F, et al. (2003) Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res 23: 2077-2083.
13. Bar-Yehuda S, Barer F, Volfsson L, Fishman P, (2001) Resistance of muscle to tumor metastases: a role for A3 adenosine receptor agonists. Neoplasia 3: 125-131.
14. Cohen S, Stemmer S, Zozulya G, Ochaion A, Patoka R, et al. (2011) CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 226: 2438-2447.
15. Fishman P, Bar-Yehuda S, Barer F, Madi L, Multani AS, et al. (2001) The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 269: 230-236.
16. Panjehpour M, Karami-Tehrani F, (2007) Adenosine modulates cell growth in the human breast cancer cells via adenosine receptors. Oncol Res 16: 575-585.
17. Morello S, Sorrentino R, Porta A, Forte G, Popolo A, et al. (2009) Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells. J Cell Physiol 221: 378-386.
18. Jajoo S, Mukherjea D, Watabe K, Ramkumar V, (2009) Adenosine A3 receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. Neoplasia 11: 1132-1145.
19. Hardell L, Sage C, (2008) Biological effects from electromagnetic field exposure and public exposure standards. Biomed Pharmacother 62: 104-109.
20. Massot O, Grimaldi B, Bailly JM, Kochanek M, Deschamps F, et al. (2000) Magnetic field desensitizes 5-HT(1B) receptor in brain: pharmacological and functional studies. Brain Res 858: 143-150.
21. Tebano MT, Martire A, Rebola N, Pepponi R, Domenici MR, et al. (2005) Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartete effects. J Neurochem 95: 1188-1200.
22. Varani K, Gessi S, Merighi S, Iannotta V, Cattabriga E, et al. (2002) Effect of low frequency electromagnetic fields on A2A adenosine receptors in human neutrophils. Br J Pharmacol 136: 57-66.
23. Varani K, Gessi S, Merighi S, Iannotta V, Cattabriga E, et al. (2003) Alteration of A3 adenosine receptors in human neutrophils and low frequency electromagnetic fields. Biochem Pharmacol 66: 1897-1906.
24. Varani K, De Mattei M, Vincenzi F, Gessi S, Merighi S, et al. (2008) Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low Energy pulsed electromagnetic fields. Osteoarthritis Cartilage 16: 292-304.
25. De Mattei M, Varani K, Masieri FF, Pellati A, Ongaro A, et al. (2009) Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts. Osteoarthritis Cartilage 17: 252-262.
26. García AM, Sisternas A, Hoyos SP, (2008) Occupational exposure to extremely low frequency electric and magnetic fields and Alzheimer disease: a meta-analysis. Int J Epidemiol 37: 329-340.
27. Arendash GW, Sanchez-Ramos J, Mori T, Mamcarz M, Lin X, et al. (2010) Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice. J Alzheimers Dis 19: 191-210.
28. Wang X, Michaelis ML, Michaelis EK, (2010) Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385. Plos One 5: e13883.
29. Rohde C, Chiang A, Adipoju O, Casper D, Pilla AA, (2010) Effects of pulsed electromagnetic fields on interleukin-1 beta and postoperative pain: a double-blind, placebo-controlled, pilot study in breast reduction patients. Plast Reconstr Surg 125: 1620-1629.
30. Chen G, Upham BL, Sun W, Chang CC, Rothwell EJ, et al. (2000) Effect of electromagnetic field exposure on chemically induced differentiation of friend erythroleukemia cells. Environ Health Perspect 108: 967-972.
31. Girgert R, Schimming H, Korner W, Grundker C, Hanf V, (2005) Induction of tamoxifen resistance in breast cancer cells by ELF electromagnetic fields. Biochem Biophys Res Commun 336: 1144-1149.
32. Yasui M, Kikuchi T, Ogawa M, Otaka Y, Tsuchitani M, et al. (1997) Carcinogenicity test of 50 Hz sinusoidal magnetic fields in rats. Bioelectromagnetics 18: 531-540.
33. Galloni P, Marino C, (2000) Effects of 50 Hz magnetic field exposure on tumor experimental models. Bioelectromagnetics 21: 608-614.
34. Barbault A, Costa FP, Bottger B, Munden RF, Bomholt F, et al. (2009) Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res 28: 51.
35. Williams CD, Markov MS, Hardman WE, Cameron IL, (2001) Therapeutic electromagnetic field effects on angiogenesis and tumor growth. Anticancer Res 21: 3887-3891.
36. Cameron IL, Sun LZ, Short N, Hardman WE, Williams CD, (2005) Therapeutic Electromagnetic Field (TEMF) and gamma irradiation on human breast cancer xenograft growth, angiogenesis and metastasis. Cancer Cell Int 5: 23.
37. Rannug A, Holmberg B, Ekstrom T, Mild KH, (1993) Rat liver foci study on coexposure with 50 Hz magnetic fields and known carcinogens. Bioelectromagnetics 14: 17-27.
38. Jiménez-García MN, Arellanes-Robledo J, Aparicio-Bautista DI, Rodríguez-Segura MA, Villa-Treviño S, et al. (2010) Anti-proliferative effect of extremely low frequency electromagnetic field on preneoplastic lesions formation in the rat liver. BMC Cancer 10: 159.
39. Wen J, Jiang S, Chen B, (2011) The effect of 100 Hz magnetic field combined with X-ray on hepatoma-implanted mice. Bioelectromagnetics 32: 322-324.
40. Hirata M, Kusuzaki K, Takeshita H, Hashiguchi S, Hirasawa Y, et al. (2001) Drug resistance modification using pulsing electromagnetic field stimulation for multidrug resistant mouse osteosarcoma cell line. Anticancer Res 21: 317-320.
41. Gartlon J, Kinsner A, Bal-Price A, Coecke S, Clothier RH, (2006) Evaluation of a proposed in vitro test strategy using neuronal and non-neuronal cell systems for detecting neurotoxicity. Toxicol In Vitro 20: 1569-1581.
42. Varani K, Vincenzi F, Targa M, Corciulo C, Fini M, et al. (2012) Effect of pulsed electromagnetic field exposure on adenosine receptors in rat brain. Bioelectromagnetics 33: 279-287.
43. Schneider G, Henrich A, Greiner G, Wolf V, Lovas A, et al. (2010) Cross talk between stimulated NF-kappaB and the tumor suppressor p53. Oncogene 29: 2795-806.
44. Aghaei M, Panjehpour M, Karami-Tehrani F, Salami S, (2011) Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. J Cancer Res Clin Oncol 137: 1511-1523.
45. Kim SJ, Min HY, Chung HJ, Park EJ, Hong JY, et al. (2008) Inhibition of cell proliferation through cell cycle arrest and apoptosis by thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, in human lung cancer cells. Cancer Lett 264: 309-315.
46. Bar-Yehuda S, Madi L, Silberman D, Gery S, Shkapenuk M, et al. (2005) CF101, an agonist to the A3 adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. Neoplasia 7: 85-90.
47. Fishman P, Bar-Yehuda S, Ohana G, Pathak S, Wasserman L, et al. (2000) Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur J Cancer 36: 1452-1458.
48. Ongaro A, Varani K, Masieri FF, Pellati A, Massari L, et al. (2012) Electromagnetic fields (EMFs) and adenosine receptors modulate prostaglandin E(2) and cytokine release in human osteoarthritic synovial fibroblasts. J Cell Physiol 227: 2461-2469.
49. Radeva M, Berg H, (2004) Differences in lethality between cancer cells and human lymphocytes caused by LF-electromagnetic fields. Bioelectromagnetics 25: 503-507.
50. Jiménez-García MN, Arellanes-Robledo J, Aparicio-Bautista DI, Rodríguez-Segura MA, Villa-Treviño S, et al. (2010) Anti-proliferative effect of extremely low frequency electromagnetic field on preneoplastic lesions formation in the rat liver. BMC Cancer 10: 159.
51. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB, (2011) NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30: 1615-1630.
52. Belardo G, Piva R, Santoro MG, (2010) Heat stress triggers apoptosis by impairing NF-kappaB survival signaling in malignant B cells. Leukemia 24: 187-196.
53. Melo JB, Agostinho P, Oliveira CR, (2007) Prion protein aggregation and neurotoxicity in cortical neurons. Ann N Y Acad Sci 1096: 220-229.
54. Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, et al. (2010) A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. Faseb J 24: 587-598.
55. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, et al. (2006) Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol 72: 19-31.
56. Varani K, Merighi S, Gessi S, Klotz KN, Leung E, et al. (2000) [3H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mol Pharmacol 57: 968-975.
57. Varani K, Gessi S, Merighi S, Vincenzi F, Cattabriga E, et al. (2005) Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol 70: 1601-1612.
58. Varani K, Maniero S, Vincenzi F, Targa M, Stefanelli A, et al. (2011) A3 receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway. Am J Respir Crit Care Med 183: 522-530.
59. Kuo PL, Chiang LC, Lin CC, (2002) Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci 72: 23-34.
60. Varani K, Caramori G, Vincenzi F, Tosi A, Barczyk A, et al. (2010) Oxidative/nitrosative stress selectively altered A2B adenosine receptors in chronic obstructive pulmonary disease. Faseb J 24: 1192-1204.